HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Glenmark gets USFDA’s tentative approval for Nintedanib Capsules
Jun-25-2021

Glenmark Pharmaceuticals has received tentative approval by the United States Food & Drug Administration (USFDA) for Nintedanib Capsules, 100 mg and 150 mg, the generic version of Ofev Capsules, 100 mg and 150 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

According to IQVIATM sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales of approximately $1.6 billion.

Glenmark’s current portfolio consists of 172 products authorized for distribution in the U.S. marketplace and 44 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

  RELATED NEWS >>